CRISPR Therapeutics (CRSP) Tops Q4 EPS by 88c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.41), $0.88 better than the analyst estimate of ($2.29). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.12 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Sun Communities completes $1.03B sale of Park Holidays to Aermont
• AI and earnings keep driving markets as focus shifts to Trump-Xi summit